While BioXcel Therapeutics Inc has underperformed by -7.61%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BTAI fell by -87.14%, with highs and lows ranging from $5.62 to $0.50, whereas the simple moving average fell by -60.05% in the last 200 days.
On February 21, 2024, UBS Downgraded BioXcel Therapeutics Inc (NASDAQ: BTAI) to Neutral. A report published by Mizuho on August 15, 2023, Downgraded its rating to ‘Neutral’ for BTAI. Jefferies March 10, 2023d the rating to Hold on March 10, 2023, and set its price target from $20 to $22. Goldman December 01, 2022d its ‘Sell’ rating to ‘Neutral’ for BTAI, as published in its report on December 01, 2022. Mizuho’s report from July 07, 2022 suggests a price prediction of $19 for BTAI shares, giving the stock a ‘Buy’ rating. BofA Securities also rated the stock as ‘Buy’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of BioXcel Therapeutics Inc (BTAI)
Further, the quarter-over-quarter increase in sales is 141.58%, showing a positive trend in the upcoming months.
In order to gain a clear picture of BioXcel Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -1766.94% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.25, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 478.69K can be a very valuable indicator of volatility for BTAI stock. On a monthly basis, the volatility of the stock is set at 8.94%, whereas on a weekly basis, it is put at 10.61%, with a loss of -1.74% over the past seven days. Furthermore, long-term investors anticipate a median target price of $4.20, showing growth from the present price of $0.67, which can serve as yet another indication of whether BTAI is worth investing in or should be passed over.
How Do You Analyze BioXcel Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 20.29%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 23.68% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BTAI shares are owned by institutional investors to the tune of 23.68% at present.
